JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma ...

Market Size and Growth: Analysis of the current market size and projections for the cancer monoclonal antibody market from 2023 to 2032. This includes data on market value and volume, as well as the ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

The researchers compared Rituximab (RTX), a Type I first-generation mouse/human chimeric monoclonal antibody, to Ofatumumab (OFA), a Type I second-generation fully human monoclonal antibody ...

Researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor ... Researchers also tested monoclonal antibodies to block or neutralize the IL-4 ...

While chimeric antigen receptor (CAR) T-cells and monoclonal antibodies have shown great promise in treating blood malignancies by targeting antigens on rogue cells, their use with AML is hindered ...

‘The monoclonal antibody VIR-3434 discovered targeted the ... Investigating VIR-3434's Efficacy Through Human Liver-Chimeric Mouse Model The researchers then tested VIR-3434’s neutralization ...

beginning with the mouse monoclonal antibody Muromonab-CD3 for kidney transplant rejection. 3 In additional to antibodies from mice and humans, researcher have produced chimeric and humanized ...

Serum antibody levels were sustained longer after the fourth infusion than after the first, and were higher in responders and in patients with lower tumor burden. The majority of adverse events ...